망막용 의약품 시장 : 약물 계열별, 적응증별, 투여 경로별, 지역별

Retinal Drugs Market is estimated to be valued at USD 24.18 Bn in 2026 and is expected to reach USD 41.17 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.9% from 2026 to 2033.

The global retinal drugs market is a fast-growing segment of the ophthalmology and pharmaceutical industries, covering therapies for major retinal diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and inherited retinal diseases. The market comprises anti-VEGF agents, corticosteroids, complement inhibitors, and emerging gene-based therapies that target various retinal disease mechanisms.

Increasing aging population worldwide, increasing prevalence of diabetes, and increasing burden of vision-threatening retinal disorders are aiding the market growth. Meanwhile, advancements in sustained drug-delivery systems, biosimilars, gene therapies, and precision treatment approaches are expanding the therapeutic options and reshaping the retinal disease treatment landscape.

Market Dynamics

The global retinal drugs market is driven by rising incidence of retinal diseases, especially age-related macular degeneration (AMD) and diabetic retinopathy, and increasing demand for effective treatments to preserve vision. The anti-VEGF treatment continues to dominate the market, with new longer-acting formulations and increased funding for retinal gene therapies driving market growth, while improved retinal-care infrastructure is expanding treatment availability.

However, the growth of retinal drugs market is limited by factors such as high treatment costs, reimbursement limitations and procedural burden of intravitreal administration. Nevertheless, patent expiries are opening up opportunities for biosimilars, while advances in sustained-release implants, novel delivery systems and gene therapies are providing new avenues for innovation, emerging markets across Asia Pacific, Latin America and Middle East & Africa also offer significant growth potential.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global retinal drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Amgen Inc., Santen Pharmaceutical Co., Ltd., Bausch + Lomb Corporation, and Astellas Pharma Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global retinal drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global retinal drugs market

Market Segmentation

• Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
• Anti-VEGF Agents
• Corticosteroids
• Complement Inhibitors
• Others
• Indication Insights (Revenue, USD Bn, 2021 - 2033)
• Age-Related Macular Degeneration (AMD)
• Diabetic Retinopathy / Diabetic Macular Edema (DME)
• Retinal Vein Occlusion (RVO)
• Inherited Retinal Diseases
• Others
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Intravitreal
• Subretinal
• Others
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Regeneron Pharmaceuticals, Inc.
• Hoffmann-La Roche Ltd
• Novartis AG
• AbbVie Inc.
• Bayer AG
• Apellis Pharmaceuticals, Inc.
• Amgen Inc.
• Santen Pharmaceutical Co., Ltd.
• Bausch + Lomb Corporation
• Astellas Pharma Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Retinal Drugs Market, By Drug Class
  • Global Retinal Drugs Market, By Indication
  • Global Retinal Drugs Market, By Route of Administration
  • Global Retinal Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Industry Trends

4. Global Retinal Drugs Market, By Drug Class, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Anti-VEGF Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Complement Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Retinal Drugs Market, By Indication, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Age-Related Macular Degeneration (AMD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Diabetic Retinopathy / Diabetic Macular Edema (DME)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Retinal Vein Occlusion (RVO)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Inherited Retinal Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Retinal Drugs Market, By Route of Administration, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Intravitreal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Subretinal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Retinal Drugs Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Company Profile
  • Regeneron Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Apellis Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Santen Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bausch + Lomb Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us